Foscarnet for suppression of human immunodeficiency virus replication

C V Fletcher, A C Collier, F S Rhame, D Bennett, M F Para, C C Beatty, C E Jones, H H Balfour Jr, C V Fletcher, A C Collier, F S Rhame, D Bennett, M F Para, C C Beatty, C E Jones, H H Balfour Jr

Abstract

The effect of foscarnet against human immunodeficiency virus (HIV) was evaluated in nine HIV-infected individuals; six completed 28 days of induction therapy. The overall mean increase in CD4+ lymphocytes was 64 cells per mm3. The mean decline in the HIV antigen concentration was 108 pg/ml (P = 0.03), and suppression was related to systemic foscarnet exposure by a maximum-effect pharmacodynamic model.

References

    1. Clin Pharmacol Ther. 1979 Sep;26(3):294-305
    1. Clin Pharmacokinet. 1981 Nov-Dec;6(6):429-53
    1. Lancet. 1985 Jun 29;1(8444):1480-2
    1. Clin Pharmacol Ther. 1988 Jul;44(1):65-73
    1. Comput Methods Programs Biomed. 1988 Jul-Aug;27(1):47-54
    1. J Infect Dis. 1988 Oct;158(4):862-5
    1. Antimicrob Agents Chemother. 1992 Aug;36(8):1773-8
    1. Antimicrob Agents Chemother. 1989 May;33(5):742-5
    1. Antimicrob Agents Chemother. 1989 May;33(5):778-80
    1. Antimicrob Agents Chemother. 1989 Jul;33(7):1023-31
    1. Ann Intern Med. 1991 Nov 1;115(9):665-73
    1. J Infect Dis. 1992 Sep;166(3):607-10
    1. J Chromatogr. 1989 Mar 24;488(2):447-55

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever